| Status | Topic selection |
| Technology type | Medicine |
| Decision | Not selected |
| Reason for decision | Not eligible for Health Technology Evaluation guidance |
| Further information | Following information received from the company that the extension to their marketing authorisation for semaglutide will not add a significant new therapeutic indication. This technology does not meet the eligibility criteria for selection for technology appraisal and will subsequently be removed from the work programme. |
| ID number | 11788 |
Project Team
| Project lead | Abigail Stephens |
Email enquiries
- If you have any queries please email topic.selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 March 2023 | Topic selection. Changed as now not selected |
| 09 January 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on how we select topics for development, please see our page about topic selection